Human papillomavirus genotype distribution in low-grade squamous intraepithelial lesion cytology, and its immediate risk for high-grade cervical lesion or cancer: a single-center, cross-sectional study

Nida Jareemit, MD1, Navin Horthongkham, PhD, MSc2, Suwanit Therasakvichya, MD1, Boonlert Viriyapak, MD1, Perapong Inthasorn, MD1, Mongkol Benjapibal, MD1, Vuthinun Achariyapota, MD1, Irene Ruengkhachorn, MD1

1Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, 2Department of Microbiology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand

Objective
To investigate the distribution of human papillomavirus (HPV) genotypes in low-grade squamous intraepithelial lesion (LSIL) cytology and the immediate risk of cervical intraepithelial neoplasia grade 2 or higher (CIN2+) lesions.

Methods
This prospective cross-sectional study enrolled women aged ≥21 years that were diagnosed with LSIL cytology at Siriraj Hospital (Bangkok, Thailand) during 2017-2019. Anyplex II HPV testing was performed to detect 14 high-risk HPV cases prior to colposcopy-directed biopsy.

Results
In total, 318 patients were included in the final analysis. Of those, 24 (7.5%), 241 (75.8%), 53 (16.7%) were aged 21-25 years, 25-50 years, and ≥50 years, respectively. Eighty-two patients (25.8%) had abnormal screening results within the previous 5 years. High-risk HPV infection was found in 188 patients (59.1%) with 127 (39.9%) having single and 61 (19.2%) having multiple infections. The five most common HPV genotypes were HPV 66 (18.6%), HPV51 (9.7%), HPV58 (9.4%), HPV16 (9.1%), and HPV56 (8.2%). The immediate risk of CIN2+ was 6% in LSIL, regardless of the HPV status, 8% in high-risk HPV-positive LSIL, and 3.1% in high-risk HPV-negative LSIL. When using 6% as the threshold risk for colposcopy, performing reflex HPV testing in LSIL cytology can decrease the number of coloscopies by 40.9%, with an area under the receiver operating characteristic curve of 0.6 (95% confidence interval, 0.5-0.7).

Conclusion
The study findings support the idea that geographic variations affect the HPV genotype. Reflex HPV testing may decrease the number of coloscopies in cytology-based screening regions with a high prevalence of low-carcinogenic HPV.

Keywords: Human papillomavirus; Genotype; Cervical intraepithelial neoplasia; Prevalence; Colposcopy
Introduction

Cervical cancer is the fourth most common cancer and the leading cause of cancer-related deaths among women worldwide [1]. Cervical cancer screening is one of the most effective types of cancer screening, as evidenced by a substantial decline in both the incidence and mortality associated with it, since the formal publication of the validated Papanicolaou (Pap) smear in 1943 [2,3]. During the 1990s, human papillomavirus (HPV), a sexually transmitted viral infection, emerged as the most important risk factor for the development of preinvasive and invasive cervical cancer [4]. As such, the improved ability to identify and understand HPV has had a tremendous effect for the development of prevention and screening strategies for cervical cancer. HPV vaccines have been developed for carcinogenic and high-risk HPV. Moreover, HPV testing has been added as a component of cervical cancer screening to be used alone or as an adjunctive test to increase the sensitivity for detecting preinvasive and invasive cervical cancer [5-8]. Recent guidelines recommend that women with abnormal cervical cancer screening should be managed according to each patient’s estimated risk of high-grade squamous intraepithelial lesion (HSIL) histology or cervical cancer [9-11]. The risk is estimated based on all available screening test results.

In many countries, cervical cytology alone is still the most widely used method for cervical cancer screening [4]. HPV testing in high-grade cytology is considered less important. However, among women with low-grade cytology (i.e., atypical squamous cells of undetermined significance [ASCUS] and low-grade squamous intraepithelial lesion [LSIL]), reflex HPV testing may be beneficial for triaging patients to immediate colposcopy or more conservative wait-and-see surveillance. The American Society for Colposcopy and Cervical Pathology (ASCCP) guidelines recommend reflex HPV testing in ASCUS because HPV testing identifies approximately 90% of ASCUS cases diagnosed with HSIL histology. Furthermore, up to two-thirds of women with ASCUS were negative for high-risk HPV infection, which means that women with a low risk for HSIL histology or cancer may not require colposcopy. As a result, reflex HPV testing in ASCUS can lower the colposcopy rate by half [12,13]. In contrast, in LSIL cytology, the immediate risk for HSIL histology or cancer is below the threshold for immediate colposcopy only if high-risk HPV tests are negative. Because of the higher prevalence (81-83%) of carcinogenic HPV infection in LSIL, reflex HPV testing does not lower the colposcopy rate as much as ASCUS [14-17]. Consequently, the ASCCP guidelines do not recommend HPV triage for LSIL cytology. However, the ASCCP guidelines are based on data collected only from American women. Since there might be geographic variations in both HPV genotype distribution and the risk conferred by each genotype to high-grade lesions or cancer, local management guidelines should be developed based on local HPV epidemiology. Therefore,

---

**Fig. 1.** Flow diagram summarizing the enrollment of the study population. LSIL, low-grade squamous intraepithelial lesion; HPV, human papillomavirus.
it is essential for each region to investigate and understand its own specific HPV genotype prevalence and to understand which prevalent HPV genotypes influence significant clinical effects on women living in that region.

The aim of this study was to investigate HPV genotype distribution in LSIL cytology and the immediate risk of cervical intraepithelial neoplasia grade 2 or higher (CIN2+) lesions caused by the corresponding HPV genotype. Knowing the HPV status and its clinical significance relative to the increased risk of CIN2+ lesions may be useful for determining the role of HPV triage in cytology-based cervical cancer screening based on local HPV epidemiology. Furthermore, HPV genotype prevalence can provide important data for targeting the carcinogenic HPV genotypes during HPV vaccine production.

**Materials and methods**

1. **Ethics statement**
The study protocol was approved by the Siriraj Institutional Review Board (SIRB) of the Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand (COA No. Si 060/2017). All study participants provided written informed consent prior to enrollment.

2. **Study design and study participants**
This prospective cross-sectional study was conducted at Siriraj Hospital, Thailand’s largest university-based national tertiary referral center. In our center, liquid-based cervical cytology is the most commonly used cervical cancer screening technique. It is our practice to recommend colposcopies for all women with LSIL cytology. Women aged 21 years or older with LSIL cervical cytology who attended our colposcopy clinic between February 7, 2017 and February 7, 2019, were invited to enroll in this study before colposcopy was performed. Pregnant patients and those diagnosed with cervical cancer were excluded.

3. **Specimen collection**
HPV genotyping was performed at our colposcopy clinic prior to colposcopy assessment. Cervical samples were evaluated using an Anyplex II HPV HR Detection Kit (Seegene, Seoul, Korea) according to the manufacturer’s instructions. Multiplex real-time polymerase chain reaction design using tagging oligonucleotide cleavage and extension technology allowed the simultaneous detection and genotyping of 14 high-risk HPV genotypes (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68) and an internal control (human beta-globin) in a single reaction. Colposcopy-directed biopsy was

| Characteristic                          | Value  |
|----------------------------------------|--------|
| Age (yr)                               | 39.2±10.3 |
| 21-24                                  | 24 (7.5)  |
| 25-29                                  | 35 (11.0) |
| 30-49                                  | 206 (64.8) |
| ≥50                                    | 53 (16.7)  |
| Menopause                              | 34 (10.7)  |
| Cervical cancer screening within the previous 5 years |        |
| No or unknown                          | 153 (48.1) |
| Yes (normal screening)                 | 83 (26.1)  |
| Yes (abnormal screening)               | 82 (25.8)  |
| CIN2+ lesion within the previous 5 years | 2 (0.6)    |

| Transformation zone                    |        |
| Type 1                                 | 252 (79.2) |
| Type 2                                 | 39 (12.3)  |
| Type 3                                 | 27 (8.5)   |

| Colposcopic finding                    |        |
| Normal                                 | 162 (50.9) |
| Low-grade lesion                       | 135 (42.5) |
| High-grade lesion                      | 21 (6.6)   |
| Cancer                                 | 0 (0.0)    |

| High-risk HPV infection                |        |
| Yes                                    | 188 (59.1) |
| Single infection                       | 127 (39.9) |
| Multiple infections                    | 61 (19.2)  |

| Cervical histopathology                |        |
| No SIL                                 | 197 (61.9) |
| LSIL                                   | 102 (32.1) |
| HSIL                                   | 18 (5.7)   |
| Cancer                                 | 1 (0.3)    |

Values are presented as number (%) or mean±standard deviation. CIN2+, cervical intraepithelial neoplasia 2 or higher lesions; HPV, human papillomavirus; SIL, squamous intraepithelial lesion; LSIL, low-grade squamous intraepithelial lesion; HSIL, high-grade squamous intraepithelial lesion.
performed during colposcopy in all study participants. In cases where no abnormal cervical lesions were detected, random biopsy was performed. Endocervical sampling was not a mandatory component of this study and was performed in cases of inadequate transformation zone, inadequate colposcopy, or endocervical involvement. Colposcopy procedures were performed under the supervision of experienced colposcopists or gynecologic oncologists. Further management was performed according to local guidelines. The normal protocol at our center is to repeat cervical cytology at 1 year in patients with LSIL cytology with low-grade histology and immediate cervical ablation or conization in patients with high-grade histology with LSIL cytology.

4. Data collection
Prospectively collected data included baseline characteristics, prior cervical cancer screening results, HPV genotyping, colposcopic findings, and cervical histopathology. During the study period, a 2-tiered terminology system was employed (histologic LSIL or HSIL) to report on cervical histopathology according to the Lower Anogenital Squamous Terminology (LAST) Project recommendation [18].

5. Statistical analysis
Continuous variables were presented as mean±standard deviation for normally distributed data, and median and interquartile range were used to describe non-normally distributed data. Categorical variables were presented as frequencies and percentages. Simple proportions were used to establish the risk of CIN2+ lesion values using standard methods to generate a 95% confidence interval (CI). A chi-square test was performed to explore differences in proportions. In cases where at least one cell had a frequency of 5 or less, Fisher’s exact test was used. This study further explored the differences in the detection of CIN2+ lesions and the number of colposcopies if different types of reflex HPV testing were used. The sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and overall accuracy were calculated and reported with their respective 95% CIs. The diagnostic performance was compared between tests using McNemar’s exact probability test. A P-value <0.05 was considered to be statistically significant for all tests. Statistical analyses were performed using PASW Statistics version 23 (IBM Corp., Armonk, NY, USA).

Results
A total of 323 patients with LSIL were identified, but five patients were excluded from the study (Fig. 1). Of these five patients, two did not have LSIL cytology and three did not undergo HPV genotyping. The demographic and clinical characteristics of the women in our study are summarized in Table 1. The mean age of the patients was 39.2±10.3

![Fig. 2. Human papillomavirus (HPV) genotype distribution in this study’s Thai low-grade squamous intraepithelial lesion cohort. HR, high risk.](image)
years, and approximately 81.4% of patients were 30 years old or older. Only 10.7% of the patients were menopausal. Less than half of the patients (48.1%) had no cervical cancer screening or an unknown screening result within the preceding 5 years. Among the 165 patients with available screening results, 83 had normal and 82 had abnormal screening results. Only two patients (0.6%) had a prior diagnosis of CIN2+ lesions.

All patients underwent colposcopy and cervical biopsy. An adequate transformation zone was observed in 252 (79.2%) patients. Normal colposcopic findings, low-grade lesions, and high-grade lesions were observed in 162 (50.9%), 135 (42.5%), and 21 (6.6%) patients, respectively. The number of cervical biopsies ranged from one to four. Endocervical curettage was performed in 41 patients (12.9%), and no CIN2+ lesions were found in the endocervical samples. Histologically confirmed CIN2+ lesions were reported in 6% (19/318) of the patients. One of the 19 patients, who was 46 years old, had adenocarcinoma of the cervix, which was detected using a loop electrosurgical excision procedure (LEEP). Screening performed within the preceding 5 years revealed high-risk HPV-positive (non-16/18) and ASCUS. Recent screening showed HPV18 positivity and LSIL. A colposcopy-directed biopsy revealed adenocarcinoma in situ.

The prevalence of any of the 14 high-risk HPV infections in this LSIL cohort was 59.1% (188/318). HPV66 was the most commonly identified genotype (18.6%), followed by HPV51 (9.7%), HPV58 (9.4%), HPV16 (9.1%), HPV56 (8.2%), HPV52 (7.9%), HPV18 (4.7%), HPV39 (4.4%), HPV59 (3.8%), HPV33 (3.1%), HPV68 (2.8%), HPV31 (2.5%), HPV45 (0.9%), and HPV35 (0.6%) (Fig. 2). A single high-risk HPV infection was observed in 127 patients (39.9%), whereas 61 (19.2%) had multiple high-risk HPV infections (Table 1).

### Table 2. The immediate risk of CIN2+ lesion according to HPV status in LSIL patients (n=318)

| HPV status                  | Immediate risk of CIN2+ lesion (%) [95%CI] |
|-----------------------------|------------------------------------------|
| Regardless of HPV status    | 6 (3.6-9.2)                              |
| HPV HR-                     | 3.1 (0.8-7.7)                            |
| HPV HR+                     | 8 (4.5-12.8)                             |
| HPV16+                      | 20.7 (8.39-7.7)                          |
| HPV18+                      | 13.3 (1.7-10.5)                          |
| HPV 16/18+                  | 16.7 (7-31.4)                            |
| HPV HR non-16/18+          | 5.5 (2.4-10.5)                           |
| HPV68+                      | 11.2 (0.3-48.2)                          |
| HPV33+                      | 10 (0.3-44.5)                            |
| HPV52+                      | 8 (1-26)                                 |
| HPV56+                      | 7.7 (0.9-25.1)                           |
| HPV39+                      | 7 (2-33.9)                               |
| HPV58+                      | 6.7 (0.8-22.1)                           |
| HPV51+                      | 6.5 (0.8-21.4)                           |
| HPV66+                      | 5.1 (1.1-14.1)                           |
| HPV31+                      | 0 (0-36.9)                               |
| HPV35+                      | 0 (0-84.2)                               |
| HPV45+                      | 0 (0-70.8)                               |
| HPV59+                      | 0 (0-26.5)                               |

CIN2+, cervical intraepithelial neoplasia 2 or higher lesion; HPV, human papillomavirus; LSIL, low-grade squamous intraepithelial lesion; CI, confidence interval; HR, high risk; -, negative; +, positive.

### Table 3. Number of colposcopies and colposcopic diagnostic performance relative to the detection of CIN2+ lesion by type of HPV testing using a clinical action threshold for colposcopy of 6%

| Type of HPV testing | Number of colposcopies | Sensitivity (% [95%CI]) | Specificity (% [95%CI]) | PPV (% [95%CI]) | NPV (% [95%CI]) | AUROC |
|---------------------|------------------------|--------------------------|--------------------------|-----------------|-----------------|-------|
| No HPV testing      | 318 (100.0)            |                          |                          |                 |                 |       |
| HPV testing         | 188 (59.1)             | 78.9 (53.9-93)           | 42.1 (36.5-47.9)         | 8 (4.7-13)      | 96.9 (91.8-99)  | 0.60  |
| Partial HPV genotyping | 42 (13.2)         | 10.5 (1.3-33.1)          | 95.2 (92-97.4)           | 13.3 (7-40.5)   | 93.8 (90.3-96.4)| 0.53  |
| HPV genotyping      | 142 (44.7)             | 31.6 (12.6-56.6)         | 59.9 (53.8-65.8)         | 5.2 (1.9-11)    | 92.6 (87.7-96)  | 0.46  |

$$P$$-value <0.001 0.149

CIN2+, cervical intraepithelial neoplasia 2 or higher lesion; HPV, human papillomavirus; CI, confidence interval; PPV, positive predictive value; NPV, negative predictive value; AUROC, area under the receiver operating characteristic curve.  
*HPV testing was reported using two categories: negative 14 high-risk HPV or positive any of 14 high-risk HPV (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and/or 68); Partial HPV genotyping was reported using three categories: negative 14 high-risk HPV, positive HPV16/18, or positive non-HPV16/18; HPV genotyping was reported as specific genotype.
The immediate risk of CIN2+ lesions, according to the HPV status of patients with LSIL, is shown in Table 2. In patients with LSIL, regardless of the HPV status, the immediate CIN2+ risk was estimated to be 6% (95% CI, 3.6-9.2). The immediate CIN2+ risk was 8% (95% CI, 4.5-12.8) in those positive for any of the 14 high-risk HPV genotypes, and 3.1% (95% CI, 0.8-7.7) in those negative for all 14 high-risk HPV genotypes. The immediate CIN2+ risks were 20.7% (95% CI, 8.3-39.7) in HPV16-positive, 13.3% (95% CI, 1.7-10.5) in HPV18-positive, 16.7% (95% CI, 7.3-31.4) in HPV16/18-positive, and 5.5% (95% CI, 2.4-10.5) in high-risk non-HPV16/18-positive patients. The immediate CIN2+ risk of HPV66 positivity, which is the most prevalent HPV genotype in this study, was 5.1% (95% CI, 1.1-14.1). It is important to recognize that the estimated risk of CIN2+ is limited in women with multiple HPV infections.

The threshold risk for CIN2+ lesions has not yet been conclusively defined and established; however, the ASCCP guidelines recommend immediate colposcopy in those at or above the threshold for HPV-positive ASCUS or LSIL regardless of HPV type [10,19]. In our cohort, the immediate risk of CIN2+ lesions in LSIL was 6.0%. If an immediate risk

Table 4. Clinical characteristics compared between LSIL histology and HSIL histology

| Variable                              | LSIL histology (n=299) | HSIL histology (n=19) | P-value  |
|---------------------------------------|------------------------|-----------------------|----------|
| **Age (yr)**                          |                        |                       | 0.649    |
| <30                                   | 57 (96.6)              | 2 (3.4)               |          |
| 30-49                                 | 193 (93.7)             | 13 (6.3)              |          |
| ≥50                                   | 49 (92.5)              | 4 (7.5)               |          |
| **Menopause status**                  |                        |                       | 0.132    |
| Pre-menopause                         | 269 (94.7)             | 15 (5.3)              |          |
| Menopause                             | 30 (88.2)              | 11.8                  |          |
| **Prior abnormal screening**          |                        |                       | 0.790    |
| No or unknown                         | 221 (93.6)             | 15 (6.4)              |          |
| Yes                                   | 78 (95.1)              | 4 (4.9)               |          |
| **Colposcopic finding**               |                        |                       | 0.028<sup>a</sup> |
| Normal or low-grade lesion            | 282 (94.9)             | 15 (5.1)              |          |
| High-grade lesion or cancer           | 17 (81.0)              | 4 (19.0)              |          |
| **HPV genotype**                      |                        |                       | 0.097    |
| Negative                              | 126 (96.9)             | 4 (3.1)               |          |
| Positive HPV non-16/18               | 58 (19.4)              | 7 (36.8)              |          |
| Positive HPV16/18                     | 115 (38.5)             | 8 (42.1)              |          |
| **Colposcopic finding with HPV status**|                        |                       | <0.001<sup>b</sup> |
| Low grade lesion with HPV-            | 117 (39.1)             | 4 (21.1)              |          |
| High grade lesion with HPV-           | 9 (3.0)                | 0                     |          |
| Low grade lesion with HPV+            | 165 (55.2)             | 11 (57.9)             |          |
| High grade lesion with HPV+           | 8 (2.7)                | 4 (21.1)              |          |
| **Number of high-risk HPV infections**|                        |                       | 0.172    |
| No HPV infection                      | 126 (96.9)             | 4 (3.1)               |          |
| Single infection                      | 117 (92.1)             | 10 (7.9)              |          |
| Multiple infections                   | 56 (91.8)              | 5 (8.2)               |          |

Values are presented as number (%).
LSIL, low-grade squamous intraepithelial lesion; HSIL, high-grade squamous intraepithelial lesion; HPV, human papillomavirus; -, negative; +, positive.

<sup>a</sup>P-value <0.05 indicates statistical significance.
of CIN2+ lesions of 6% is considered to be the clinical action threshold for colposcopy, patients with a risk of ≥6% should undergo colposcopy. Table 3 shows a comparison of the diagnostic performance in the detection of CIN2+ lesions and the number of colposcopies among different HPV tests used if 6% was the clinical action threshold for colposcopy. Therefore, colposcopy rates were statistically significantly different in 59.1% (188/318), 13.2% (42/318), and 44.7% (142/318) of patients if reflex HPV testing (reported as negative or positive for any of the 14 high-risk HPV), partial HPV genotyping (reported as negative 14 high-risk HPV, positive HPV16/18, or positive non-HPV16/18), and HPV genotyping (reported as a specific genotype) were used, respectively (P<0.001). The overall accuracy for the detection of CIN2+ lesions was reported as the area under the receiver operating characteristic curve (Table 3). The analysis revealed no significant difference among the three tests: 0.6 for HPV testing, 0.53 for partial HPV genotyping, and 0.46 for HPV genotyping (P=0.149). The estimated sensitivity, specificity, PPV, and NPV, according to the type of HPV testing, are shown in Table 3.

There were no significant differences in age, menopausal status, history of abnormal screening, or number of high-risk HPV infections between women with LSIL and HSIL histology (Table 4). Colposcopic findings were significantly associated with HSIL histology (P=0.028) and revealed that HPV infection was significantly more common in HSIL histology than in LSIL cytology (78.9% vs. 57.9%, P=0.097). However, combining the colposcopic impression with HPV status was significantly associated with HSIL pathology (P<0.001).

Discussion

The prevalence of high-risk HPV infection in this hospital-based Thai cohort was 59.1%. The five most common genotypes were reported to be HPV66 (18.6%), HPV51 (9.7%), HPV58 (9.4%), HPV16 (9.1%), and HPV56 (8.2%). The prevalence of high-risk HPV infection in this cohort was relatively low compared to that in previous reports from other countries/studies/studies: Korea (69.0%), China (70.8%), Brazil (76.0%), Kaiser Permanente Northern California (KPNC) (81.0%), ASC-US/LSIL Triage Study (83.0%), and the United Kingdom (83.9%) [20-25]. Concerning other studies reported from Thailand, LSIL with high-risk HPV infection was much more prevalent in Northern and Northeastern Thailand (74.8-93.3%) [26-28] compared with the rates observed in Central Thailand (46.7-54.8%) [29,30]. Furthermore, the most common HPV genotype in our study was HPV66, which differs from previous studies that reported HPV16 to be the most prevalent genotype [21,24,25,31]. In regions where high-risk non-HPV16/18 is common, a nonavalent HPV vaccine should be recommended rather than a quadrivalent one. Differences in the geographic and ethnic distributions of HPV genotypes were first proposed by Bruni et al. [32] in 2010. Other explanations that may help explain these differences in findings include variations in HPV testing techniques, HPV vaccine coverage, and source of study data (hospital-based or population-based study). The observed and reported geographic variations in HPV genotypes support the idea that management guidelines should be developed based on the regional HPV epidemiology.

The 2019 ASCCP risk-based management consensus guidelines for abnormal cervical cancer screening tests and cancer precursors proposed the principle of risk-based management [9-11]. These guidelines recommend that the clinical action threshold for surveillance, immediate colposcopy, or expedited treatment should be based on each individual patient's risk for CIN3+ lesions, in addition to the results of current and prior screening. If the immediate risk of CIN3+ is greater than or equal to 4%, immediate colposcopy is recommended. The immediate risk of CIN3+ as per the 2019 ASCCP guidelines was 1.1% in high-risk HPV-negative LSIL (surveillance recommended) and 4.3% in high-risk HPV-positive LSIL (colposcopy recommended) [9,10]. However, the immediate risk thresholds for CIN3+ were generated from the data of patients treated at centers associated with Kaiser Permanente, Northern California, USA. Thus, the generalizability of these recommendations for other populations should be further investigated.

The present study was conducted to evaluate the immediate risk of high-grade cervical lesions in the Thai LSIL population based on the HPV genotype. Although the ASCCP guideline uses CIN3 as a definition of precancer, our study used 2-tier terminology (histologic LSIL or HSIL) during the study period [10]. Therefore, CIN2 was defined as the end-point of precancer in our study. In our cohort, the immediate risk of CIN2+ was 6% (95% CI, 3.6-9.2), 8% (95% CI, 4.5-12.8), and 3.1% (95% CI, 0.8-7.7) in LSIL, HPV-positive LSIL, and HPV-negative LSIL, respectively (Table 2). In contrast, the KPNC study during 2003-2010 reported the immediate risk
of CIN2+ to be 8.7%, 10.0%, and 2.1% in LSIL with unknown HPV status, HPV-positive LSIL, and HPV-negative LSIL, respectively [22,23]. The risk of CIN2+ was lower in our LSIL cohort than that in the KPNC cohort. This might be due to the fact that the most common HPV genotype found in our study was HPV66 (20.7%) and not HPV16, which is the most highly carcinogenic HPV genotype. Our result is also inconsistent with prior studies that reported HPV16 as the most common genotype found in LSIL [24-30].

Since the immediate risk of CIN2+ in LSIL, regardless of HPV status, was used as a threshold for colposcopy, 6% was the risk cut-off. All types of HPV testing combined with LSIL cytology showed a significant decrease in colposcopy rates—decreased by 86.8% in partial HPV genotyping, 55.3% in HPV genotyping, and 40.9% in HPV testing when these tests were combined with LSIL cytology findings. Only HPV testing had an overall accuracy that met the accepted AuROC value of 0.6. Furthermore, HPV testing provided the highest NPV, which was useful for triaging patients with LSIL for colposcopy or surveillance. However, our finding-based recommendations do not coincide with those from the ASCCP guideline, which do not support performing reflex HPV testing in LSIL. This may be because of the greater prevalence of high-risk HPV and more carcinogenic genotypes, like HPV16, have been found in a USA-based population with LSIL [10,19,23]. These studies suggest that reflex HPV testing might not be as helpful in reducing the number of colposcopies in the USA population. The decision to add reflex HPV testing in patients with LSIL cytology should consider multiple factors, including genotype distribution, the clinical significance of prevalent HPV genotypes, local infrastructure, test availability, and cost-effectiveness.

The present study found no clinical factors that significantly predicted CIN2+ lesions in LSIL cytology, except for colposcopic findings alone or colposcopic findings combined with HPV status. However, in real-life clinical practice, colposcopic findings cannot be used as a prognostic tool to guide colposcopy performance. Prior studies have reported that high-risk HPV infection could help predict CIN2+ in low-grade cytology, but that previous or baseline patient characteristics could not [33-35].

However, this study has some limitations. First, the follow-up duration was relatively short. A study with a longer duration of follow-up might further clarify the cumulative risk of CIN2+ and help determine the optimal interval of surveillance. Second, CIN2 was used as an endpoint for precancer in our study. This is a drawback since CIN2 is less reproducible, less prognostic, and resolves spontaneously compared to CIN3 [36,37]. The current guidelines supports differentiating CIN2 from CIN3 within the HSIL group because this can influence clinical decision-making (i.e., conservative management, risk estimation, and surveillance) [10,38]. Finally, some low prevalence HPV genotypes were found with wide confidence intervals. Therefore, the estimated risk of CIN2+ lesions in these genotypes should be considered to be less precise. The development and implementation of screening guidelines requires data from a large nationwide population-based study with long-term follow-up data. A cost-effective analysis would also be beneficial for hospital administrators and healthcare policymakers.

In conclusion, the results of this study highlight the association of geographic variations with HPV genotypes. It suggests that population-specific guidelines should be established based on epidemiology and clinical characteristics. Reflex HPV testing may decrease the number of colposcopies in countries with a high prevalence of low carcinogenic HPV, based on cytology-based screening.

**Conflict of interest**

No potential conflict of interest relevant to this article was reported.

**Ethical approval**

The study protocol was approved by the Siriraj Institutional Review Board (SIRB) of the Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand (COA No. Si 060/2017).

**Patient consent**

All study participants provided written informed consent prior to enrollment. However, the use of images from patients are not required for the publication.
Funding information

This study was funded by a grant from the Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand (grant no. [IO] R016033013).

Acknowledgements

The authors gratefully acknowledge the women who generously agreed to participate in this study.

Author contributions

Nida Jareemit: Conceptualization, methodology, formal analysis, data curation, writing-original draft, writing-review and editing

Navin Horthongkham: Writing-review and editing

Suwanit Therasakvichya: Writing-review and editing

Boonlert Viriyapak: Writing-review and editing

Perapong Inthasorn: Writing-review and editing

Mongkol Benjapibal: Writing-review and editing

Irene Ruengkhachorn: Conceptualization, methodology, writing-review and editing

References

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021;71:209-49.
2. Vaccarella S, Lortet-Tieulent J, Plummer M, Franceschi S, Bray F. Worldwide trends in cervical cancer incidence: impact of screening against changes in disease risk factors. Eur J Cancer 2013;49:3262-73.
3. Ha HI, Chang HK, Park SJ, Lim J, Won YJ, Lim MC. The incidence and survival of cervical, ovarian, and endometrial cancer in Korea, 1999-2017: Korea Central Cancer Registry. Obstet Gynecol Sci 2021;64:444-53.
4. Safaeian M, Solomon D, Castle PE. Cervical cancer prevention--cervical screening: science in evolution. Obstet Gynecol Clin North Am 2007;34:739-60, ix.
5. Schiffman M, Solomon D. Clinical practice. Cervical-cancer screening with human papillomavirus and cytologic cotesting. N Engl J Med 2013;369:2324-31.
6. Wright TC, Stoler MH, Behrens CM, Sharma A, Zhang G, Wright TL. Primary cervical cancer screening with human papillomavirus: end of study results from the ATHENA study using HPV as the first-line screening test. Gynecol Oncol 2015;136:189-97.
7. Kong TW, Kim M, Kim YH, Kim YB, Kim J, Kim JW, et al. High-risk human papillomavirus testing as a primary screening for cervical cancer: position statement by the Korean Society of Obstetrics and Gynecology and the Korean Society of Gynecologic Oncology. Obstet Gynecol Sci 2020;63:107.
8. Fontham ETH, Wolf AMD, Church TR, Etzioni R, Fowlers CR, Herzig A, et al. Cervical cancer screening for individuals at average risk: 2020 guideline update from the American Cancer Society. CA Cancer J Clin 2020;70:321-46.
9. Egemen D, Cheung LC, Chen X, Demarco M, Perkins RB, Kinney W, et al. Risk estimates supporting the 2019 ASCCP risk-based management consensus guidelines. J Low Genit Tract Dis 2020;24:132-43.
10. Perkins RB, Guido RS, Castle PE, Chelmow D, Einstein MH, Garcia F, et al. 2019 ASCCP risk-based management consensus guidelines for abnormal cervical cancer screening tests and cancer precursors. J Low Genit Tract Dis 2020;24:102-31.
11. Schiffman M, Wentzensen N, Perkins RB, Guido RS. An introduction to the 2019 ASCCP risk-based management consensus guidelines. J Low Genit Tract Dis 2020;24:87-9.
12. ASCUS-LSIL Triage Study (ALTS) Group. Results of a randomized trial on the management of cytology interpretations of atypical squamous cells of undetermined significance. Am J Obstet Gynecol 2003;188:1383-92.
13. Solomon D, Schiffman M, Tarone R; ALTS Study group. Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial. J Natl Cancer Inst 2001;93:293-9.
14. Schiffman M, Solomon D. Findings to date from the ASCUS-LSIL triage study (ALTS). Arch Pathol Lab Med 2003;127:946-9.
15. Safaeian M, Solomon D, Wacholder S, Schiffman M, Castle P. Risk of precancer and follow-up management strategies for women with human papillomavirus-negative atypical squamous cells of undetermined significance. Obstet Gynecol 2007;109:1325-31.

16. The Atypical Squamous Cells of Undetermined Significance/Low-Grade Squamous Intraepithelial Lesions Triage Study (ALTS) Group. Human papillomavirus testing for triage of women with cytologic evidence of low-grade squamous intraepithelial lesions: baseline data from a randomized trial. J Natl Cancer Inst 2000;92:397-402.

17. ASCUS-LSIL Triage Study (ALTS) Group. A randomized trial on the management of low-grade squamous intraepithelial lesion cytology interpretations. Am J Obstet Gynecol 2003;188:1393-400.

18. Darragh TM, Colgan TJ, Cox JT, Heller DS, Henry MR, Luff RD, et al. The lower anogenital squamous terminology standardization project for HPV-associated lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology. J Low Genit Tract Dis 2012;16:205-42.

19. Massad LS, Einstein MH, Huh WK, Katki HA, Kinney WK, Schiffman M, et al. 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. J Low Genit Tract Dis 2013;17(5 Suppl 1):S1-27.

20. Kelly RS, Patnick J, Kitchener HC, Moss SM; NHSCSP HPV Special Interest Group. HPV testing as a triage for borderline or mild dyskaryosis on cervical cytology: results from the sentinel sites study. Br J Cancer 2011;105:983-8.

21. Silveira FA, Almeida G, Furtado Y, Silva KS, Maldonado P, Cavalcanti S, et al. HPV DNA genotyping and methylation of gene p16 INK4A in cervical LSIL. Exp Mol Pathol 2015;98:308-11.

22. Katki HA, Schiffman M, Castle PE, Fetterman B, Poitras NE, Lorey T, et al. Five-year risks of CIN 2+ and CIN 3+ among women with HPV-positive and HPV-negative LSIL pap results. J Low Genit Tract Dis 2013;17(5 Suppl 1):S43-9.

23. Katki HA, Schiffman M, Castle PE, Fetterman B, Poitras NE, Lorey T, et al. Benchmarking CIN 3+ risk as the basis for incorporating HPV and Pap cotesting into cervical screening and management guidelines. J Low Genit Tract Dis 2013;17(5 Suppl 1):S28-35.

24. Wang J, Tang D, Wang J, Zhang Z, Chen Y, Wang K, et al. Genotype distribution and prevalence of human papillomavirus among women with cervical cytological abnormalities in Xinjiang, China. Hum Vaccin Immunother 2019;15:1889-96.

25. Hwang HS, Park M, Lee SY, Kwon KH, Pang MG. Distribution and prevalence of human papillomavirus genotypes in routine Pap smear of 2,470 Korean women determined by DNA chip. Cancer Epidemiol Biomarkers Prev 2004;13:2153-6.

26. Ekalaksananan T, Pientong C, Kongyingyoes B, Chaiwongkot A, Yuenyao P, Kleeblaow P, et al. Combined p16INK4a and human papillomavirus testing improves the prediction of cervical intraepithelial neoplasia (CIN II-III) in Thai patients with low-grade cytological abnormalities. Asian Pac J Cancer Prev 2011;12:1777-83.

27. Khunamornpong S, Settakorn J, Sukpan K, Srisomboon J, Suprasert P, Siriaunkgul S. Performance of HPV DNA testing with hybrid capture 2 in triaging women with minor cervical cytologic abnormalities (ASC-US/LSIL) in Northern Thailand. Asian Pac J Cancer Prev 2014;15:10961-6.

28. Siriaunkgul S, Settakorn J, Sukpan K, Srisomboon J, Suprasert P, Kasatpibal N, et al. Population-based cervical cancer screening using high-risk HPV DNA test and liquid-based cytology in northern Thailand. Asian Pac J Cancer Prev 2014;15:6837-42.

29. Phoolcharoen N, Kantathavorn N, Sricharunrat T, Saeloo S, Krongthong W. A population-based study of cervical cytology findings and human papillomavirus infection in a suburban area of Thailand. Gynecol Oncol Rep 2017;21:73-7.

30. Laowahutanont P, Karalak A, Wongsema M, Loonprom K, Pukcharoen P, Jamsri P, et al. Prevalence of high risk human papillomavirus infection with different cervical cytological features among women undergoing health examination at the National Cancer Institute, Thailand. Asian Pac J Cancer Prev 2014;15:5879-82.

31. Wright TC Jr, Stoler MH, Parvu V, Yanson K, Cooper C, Andrews J. Risk detection for high-grade cervical disease using onclarity HPV extended genotyping in women, ≥21 years of age, with ASC-US or LSIL cytology. Gynecol Oncol 2019;154:360-7.
32. Bruni L, Diaz M, Castellsagué X, Ferrer E, Bosch FX, de Sanjosé S. Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. J Infect Dis 2010;202:1789-99.

33. Santos AL, Derchain SF, Martins MR, Sarian LO, Martínez EZ, Syrjänen KJ. Human papillomavirus viral load in predicting high-grade CIN in women with cervical smears showing only atypical squamous cells or low-grade squamous intraepithelial lesion. Sao Paulo Med J 2003;121:238-43.

34. Massad LS, Markwell S. Using patient history to predict high-grade cervical dysplasia and cancer in women with borderline cervical cytologic results. J Low Genit Tract Dis 2004;8:207-11.

36. Khuakoonratt N, Tangjitgamol S, Manusirivithaya S, Khunnarong J, Pataradule K, Thavaramara T, et al. Prevalence of high grade squamous intraepithelial lesion (HSIL) and invasive cervical cancer in patients with low grade squamous intraepithelial lesion (LSIL) at cervical pap smear. Asian Pac J Cancer Prev 2008;9:253-7.

36. Carreon JD, Sherman ME, Guillén D, Solomon D, Herrero R, Jerónimo J, et al. CIN2 is a much less reproducible and less valid diagnosis than CIN3: results from a histological review of population-based cervical samples. Int J Gynecol Pathol 2007;26:441-6.

37. Tainio K, Athanasiou A, Tikkinen KAO, Aaltonen R, Cárdenas J, Hernández, et al. Clinical course of untreated cervical intraepithelial neoplasia grade 2 under active surveillance: systematic review and meta-analysis. BMJ 2018;360:k499.

38. Castle PE, Adcock R, Cuzick J, Wentzensen N, Torrez-Martinez NE, Torres SM, et al. Relationships of p16 immunohistochemistry and other biomarkers with diagnoses of cervical abnormalities: implications for LAST terminology. Arch Pathol Lab Med 2020;144:725-34.